Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus.

ABSTRACT:

Background

Plasmacytoid DCs (pDC) produce large amounts of type I IFN (IFN-I), cytokines convincingly linked to systemic lupus erythematosus (SLE) pathogenesis. BIIB059 is a humanized mAb that binds blood DC antigen 2 (BDCA2), a pDC-specific receptor that inhibits the production of IFN-I and other inflammatory mediators when ligated. A first-in-human study was conducted to assess safety, tolerability, and pharmacokinetic (PK) and pharmacodynamic (PD) effects of single BIIB059 doses in healthy volunteers (HV) and patients with SLE with active cutaneous disease as well as proof of biological activity and preliminary clinical response in the SLE cohort.

Methods

A randomized, double-blind, placebo-controlled clinical trial was conducted in HV (n = 54) and patients with SLE (n =

SUBMITTER: Furie R 

PROVIDER: S-EPMC6391094 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature